William Hurley, known widely as Whurley, joins BioTalk for a deep look at how quantum computing is moving from theory into practical use across the biohealth landscape. He opens the conversation with an introduction to Strangeworks and explains why the company is focused on making quantum computing more accessible for real-world problem-solving. The discussion explores how quantum could support breakthroughs in genomics and personalized medicine, improve the way clinical trials are modeled, and strengthen manufacturing and supply chain operations. Whurley also talks through the ingredients required for regional leadership in this space, including infrastructure, strategic partnerships, and a specialized workforce. He shares his view on what will distinguish successful players in quantum from those who overpromise or misread the market, and closes with a forward look at the convergence of quantum, AI, and biotechnology and the impact these capabilities could have on healthcare innovation. The conversation follows his recent keynote appearance at the BioHealth Capital Region Forum this past September.
Listen on your favorite podcasting platforms:
Apple: https://apple.co/4ppTmml
Spotify: https://bit.ly/48pIjDt
iHeart Podcasts: https://ihr.fm/4oKdMFx
Amazon Music Podcasts: https://amzn.to/3MgH694
YouTube Music Podcasts: https://bit.ly/4pqw53G
TuneIn: https://bit.ly/4a4lJl4
Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com).
Whurley is the founder and CEO of Strangeworks, an Eisenhower Fellow, a Senior Member of the IEEE, founder of the Quantum Computing Standards Workgroup at the IEEE, the first Ambassador to CERN and Society, and co-author of “Quantum Computing for Babies” and the forthcoming “Quantum Computing for Dummies.” He previously served as a Managing Director at Goldman Sachs following its acquisition of his startup Honest Dollar. Before that he founded Chaotic Moon Studios, which was acquired by Accenture.
Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia’s growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth’s life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He also discusses Virginia’s use of public-private partnerships to accelerate industry growth, strengthen the talent pipeline, and support emerging hubs across the Commonwealth. The conversation closes with a look at Virginia’s role in the BioHealth Capital Region and how the regional identity helps amplify the state’s message as it continues building a competitive biohealth ecosystem.
The 11th Annual BioHealth Capital Region Week has been rescheduled to take place from September 23rd through 25th, 2025, at USP in Rockville, Maryland. Mark your calendars for this premier gathering of industry leaders, innovators, investors, and experts shaping the future of the biohealth industry.